This is two weeks old, but it is all I can find, too.
Zonagen Reports Third Quarter Financial Results
THE WOODLANDS, Texas--(BW HealthWire)--Oct. 28, 1999--Zonagen Inc. (Nasdaq: ZONA) (PCX:ZNG) today announced financial results for the third quarter ended September 30, 1999.
Total revenues for the third quarter ended September 30, 1999, were $607 thousand. Of this amount, $182 thousand represented product royalties received from marketing partner Schering-Plough (NYSE: SGP) for the sale of Zonagen's oral therapy product for erectile dysfunction during the second quarter of 1999. Total revenues for the same period last year, including a $5 million milestone payment received from Schering-Plough, were $5.7 million. No royalty payments were received in the same period last year. Interest income for the third quarter was $425 thousand compared to $748 thousand in the same period last year. The net loss for the quarter was $2.2 million, or $0.19 per share, versus a net income of $329 thousand, or $0.03 per share in the same period last year.
>>>>>
Note that ZONA actually received royalties from SGP for sales. Mexico? Brazil? I can see no other reason for excitement about their prospects. |
